We are live on ! Find out more
ARQT icon

Arcutis Biotherapeutics

139 hedge funds and large institutions have $1.13B invested in Arcutis Biotherapeutics in 2022 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 68 increasing their positions, 19 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,579% more call options, than puts

Call options by funds: $5.86M | Put options by funds: $349K

258% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 19

256% more capital inflows, than outflows

Capital inflows: $325M | Capital outflows: $91.5M

218% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 11

21% more funds holding

Funds holding: 115 → 139 (+24)

3.17% more ownership

Funds ownership: 95.44% → 98.61% (+3.2%)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

Holders
139
Holders Change
+24
Holders Change %
+20.87%
% of All Funds
2.38%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
35
Increased
68
Reduced
19
Closed
11
Calls
$5.86​M
Puts
$349​K
Net Calls
+$5.51​M
Net Calls Change
+$1.91​M

ARQT Hedge Fund Activity: Q3 2022 in Review

139 of the 5,834 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q3 2022, worth a combined $1.13B — up 8.5% from $1.05B a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new ARQT positions and 11 closed out — a net gain of 24 holders — while 68 added to existing stakes and 19 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $40.7M. The largest seller was OrbiMed, cutting an estimated $44.9M.

  • 139 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q3 2022, up from 115 in Q2 2022.
  • Funds reported $1.13B of Arcutis Biotherapeutics stock for Q3 2022, up 8.5% quarter-over-quarter.
  • 35 funds opened new Arcutis Biotherapeutics positions in Q3 2022 and 11 closed out, a net change of +24 holders.
  • The largest Arcutis Biotherapeutics buyer in Q3 2022 was Point72 Asset Management, an estimated $40.7M added.
  • The largest Arcutis Biotherapeutics seller in Q3 2022 was OrbiMed, an estimated $44.9M sold.

Based on aggregated 13F filings for Q3 2022.